Full description
COCOMO-ACS was a double-blind, placebo-controlled trial that randomized 64 patients (median age 61.5 years; 9.4% female) with acute non-ST-segment elevation MI to colchicine 0.5 mg daily or placebo for a median of 17.8 months in addition to guideline-recommended therapy. Participants underwent serial OCT imaging within a matched segment of non-culprit coronary artery that contained at least one lipid-rich plaque causing ≥20% stenosis. The primary outcome was the change in minimum fibrous cap thickness (FCT) in non-culprit segments from baseline to final visit.
HeSANDA 1.0.0
Collected:
Data time period: 2018 2022
Spatial Coverage And Location
text: South Australia, Victoria, Queensland, New South Wales and Western Australia
Subjects
User Contributed Tags
Login to tag this record with meaningful keywords to make it easier to discover
Other Information
South Australian Health and Medical Research Institute
Identifiers
- DOI : 10.58138/1Q2E-TD39
